{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T03:26:56Z","timestamp":1791862016048,"version":"4.3.4"},"reference-count":56,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T00:00:00Z","timestamp":1435622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:p>Sinusoidal obstruction syndrome, a complication occurring early after hematopoietic stem cell transplantation, is a concern for clinicians. There are no guidelines to direct clinicians on the optimal way to prevent and treat this disease. Newer data show that defibrotide is a promising drug both for prevention and treatment, although it is not yet FDA approved.<\/jats:p>","DOI":"10.1177\/1078155215591387","type":"journal-article","created":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T23:06:05Z","timestamp":1435705565000},"page":"496-510","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant: a review of the literature"],"prefix":"10.1177","volume":"22","author":[{"given":"Sarah A","family":"Hopps","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Oklahoma, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B","family":"Borders","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Oklahoma, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy M","family":"Hagemann","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Oklahoma, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,6,30]]},"reference":[{"key":"bibr1-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005"},{"key":"bibr2-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.06.006"},{"key":"bibr3-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13215"},{"key":"bibr4-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(93)90864-E"},{"key":"bibr5-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e32832da1e3"},{"key":"bibr6-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198809153191106"},{"key":"bibr7-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.01.002"},{"key":"bibr8-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705696"},{"key":"bibr9-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.56"},{"key":"bibr10-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61938-7"},{"key":"bibr11-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00318-1"},{"key":"bibr12-1078155215591387","first-page":"367","volume":"10","author":"Essell JH","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"bibr13-1078155215591387","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00002"},{"key":"bibr14-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(200005)64:1<32::AID-AJH6>3.0.CO;2-N"},{"key":"bibr15-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0159"},{"key":"bibr16-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703342"},{"key":"bibr17-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.11.2834.bloodjournal79112834"},{"key":"bibr18-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705297"},{"key":"bibr19-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704143"},{"key":"bibr20-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705969"},{"key":"bibr21-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02583.x"},{"key":"bibr22-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1993.tb03152.x"},{"key":"bibr23-1078155215591387","first-page":"737","volume":"92","author":"Richardson P","year":"1998","journal-title":"Blood"},{"key":"bibr24-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02475.x"},{"key":"bibr25-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1729"},{"key":"bibr26-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1216"},{"key":"bibr27-1078155215591387","doi-asserted-by":"crossref","unstructured":"Richardson PG, Tomblyn M, Kernan N, et\u00a0al. Defibrotide (DF) in the treatment of severe hepatic veno-occlusive disease (SOS) with multi-organ failure (MOF) following stem cell transplantation (SCT): results of a phase 3 study utilizing a historical control.\n                      Blood\n                      (ASH annual meeting abstract) 2009; 114: abstract 654.","DOI":"10.1182\/blood.V114.22.654.654"},{"key":"bibr28-1078155215591387","doi-asserted-by":"crossref","unstructured":"Richardson PG, Smith A, Arai S, Grupp S, Kernan NA, Adams R, et\u00a0al. Defibrotide (DF) in the treatment of severe hepatic veno-occlusive disease (SOS) with multi-organ failure (MOF): results of a treatment IND expanded access protocol.\n                      Blood\n                      2010; 116: abstract 906.","DOI":"10.1182\/blood.V116.21.906.906"},{"key":"bibr29-1078155215591387","doi-asserted-by":"crossref","unstructured":"Richardson PG, Steinbach G, Kernan N, et\u00a0al. Meta-analysis of defibrotide (DF) in the treatment of severe hepatic veno-occlusive disease (SOS) with multi-organ failure (MOF) with comparison to a historical control (HC).\n                      Blood\n                      (ASH Annual Meeting Abstracts) 2010; 116: Abstract 3481.","DOI":"10.1182\/blood.V116.21.3481.3481"},{"key":"bibr30-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704329"},{"key":"bibr31-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2007.01.075"},{"key":"bibr32-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20934"},{"key":"bibr33-1078155215591387","doi-asserted-by":"crossref","unstructured":"Corbacioglu S, Carreras E, Mohty M, et\u00a0al. Defibrotide for the treatment of hepatic veno-occlusive disease: an update from the international compassionate use program in 710 patients. In:\n                      ASBMT\n                      , San Diego, CA 11 February\u201315 February 2015, abstract no. 109, pp.S108.New York: Elsevier.","DOI":"10.1016\/j.bbmt.2014.11.135"},{"key":"bibr34-1078155215591387","doi-asserted-by":"crossref","unstructured":"Richardson P, Smith A, Triplett B, et\u00a0al. Updated results from the ongoing US treatment IND study using defibrotide for patients with hepatic veno-occlusive disease. In:\n                      ASBMT\n                      , San Diego, CA 11 February\u201315 February 2015, abstract no. 111, pp.S109. New York: Elsevier.","DOI":"10.1016\/j.bbmt.2014.11.137"},{"key":"bibr35-1078155215591387","doi-asserted-by":"crossref","unstructured":"Richardson P, Kernan N, Grupp S, et\u00a0al. Defibrotide for the treatment of severe hepatic veno-occlusive disease: an analysis of clinical benefit as determined by number needed to treat (NNT) to achieve complete response and to improve survival. In:\n                      ASBMT\n                      , San Diego, CA 11 February\u201315 February 2015, abstract no. 112, pp.S110. New York: Elsevier.","DOI":"10.1016\/j.bbmt.2014.11.138"},{"key":"bibr36-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91741-P"},{"key":"bibr37-1078155215591387","first-page":"1101","volume":"17","author":"Leahey AM","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"bibr38-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.5.1501"},{"key":"bibr39-1078155215591387","unstructured":"Goyal RK, Wall DA, Yu LC, et\u00a0al. Identification of patients with hepatic venoocclusive disease likely to respond to rtPA therapy.\n                      Blood\n                      199d; 10 (Suppl 1): 632a (abstract)."},{"key":"bibr40-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702069"},{"key":"bibr41-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198712000-00011"},{"key":"bibr42-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.101"},{"key":"bibr43-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700985"},{"key":"bibr44-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1996.5.79"},{"key":"bibr45-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(98)50003-1"},{"key":"bibr46-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e3282f2b5d9"},{"key":"bibr47-1078155215591387","first-page":"795","volume":"91","author":"Haussmann U","year":"2006","journal-title":"Haematologica"},{"key":"bibr48-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.11.011"},{"key":"bibr49-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705896"},{"key":"bibr50-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050358"},{"key":"bibr51-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701172"},{"key":"bibr52-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702387"},{"key":"bibr53-1078155215591387","unstructured":"Jazz Pharmaceuticals. Jazz pharmaceuticals initiates rolling NDA submission for defibrotide for the treatment of severe hepatic veno-occlusive disease [Article&ID=1996956], http:\/\/investor.jazzpharma.com\/phoenix.zhtml?c=210227&p=irol-news (2014, accessed 16 March 2015)."},{"key":"bibr54-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12558"},{"key":"bibr55-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199604150-00014"},{"key":"bibr56-1078155215591387","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.02.009"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215591387","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155215591387","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155215591387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:16:19Z","timestamp":1777688179000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155215591387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,30]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1177\/1078155215591387"],"URL":"https:\/\/doi.org\/10.1177\/1078155215591387","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,30]]}}}